On Nov 3, 2021 Prilenia closed a Series B round and raised $43,000,000 from ALS Investment Fund, Amplitude Venture Capital, Forbion Capital Partners, Morningside Venture Partners, Sands Capital, Sectoral Asset Management, Talisman Capital Partners, featuring lead investors Forbion Capital Partners, Morningside Venture Partners, Sands Capital.

About the company: Prilenia is located at Israel, Asia.
“Prilenia Therapeutics is a clinical stage biotech company developing its lead drug candidate, pridopidine, for Huntington’s Disease and ALS. It was founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders.”

Company website: http://www.prilenia.com